Sosei heptares' partner neurocrine biosciences initiates phase 2 clinical study evaluating nbi-1117568 in adults with schizophrenia

Tokyo and cambridge, united kingdom, oct. 28, 2022 (globe newswire) -- sosei group corporation (“the company”; tse: 4565), the world leader in g protein-coupled receptor (gpcr) focused structure-based drug design (sbdd) and development, notes its partner neurocrine biosciences inc. (“neurocrine”) announced the first patient has been randomized for its phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound nbi-1117568 in adults with schizophrenia. nbi-1117568 is an investigational, muscarinic m4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters impacted by schizophrenia.
NBIX Ratings Summary
NBIX Quant Ranking